Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:11 PM ET 10-Q
Financial Results Transportation & Logistics Systems, Inc. TLSS

Transportation & Logistics Systems Q3 2026 Results: Net Loss of $436K, Loss Widens

Transportation and Logistics Systems, Inc. reported a total shareholders' deficit of $21,999,597 as of September 30, 2026, with its primary operations classified as discontinued. The company faces significant liquidity challenges, including $7.2 million in liabilities from discontinued operations and a need for substantial additional financing to fund ongoing losses.

Key figure
Net loss $436K
4:11 PM ET Form 4
Insider Buying TPG RE Finance Trust, Inc. TRTX

TPG RE Finance Trust Director Michael Gillmore Buys $16.2K of Stock

Michael Gillmore, Director, bought 2,500 shares of TPG RE Finance Trust, Inc. at $6.50 a share, worth $16.2K in total on Nov 12, 2026. Shares held after the trade: 5,000 (+100.0%).

Value
$16.2K
Shares
2,500
Price
$6.50
Role
Director
Holding change
+100.0%
Trade date
Nov 12, 2026
4:10 PM ET Form 4
Insider Buying TPG RE Finance Trust, Inc. TRTX

TPG RE Finance Trust Director Michael Bradley Smith Buys $64.6K of Stock

Michael Bradley Smith, Director, bought 10,000 shares of TPG RE Finance Trust, Inc. at $6.45 to $6.47 a share (average $6.46) in 2 transactions, worth $64.6K in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 115,223 (+4.5%).

Value
$64.6K
Shares
10,000
Average price
$6.46
Role
Director
Holding change
+4.5%
Trade date
Nov 11, 2026 to Nov 12, 2026
4:10 PM ET Form 4
Insider Selling C4 Therapeutics, Inc. CCCC

C4 Therapeutics CFO Kendra Adams Sells $122K of Stock

Kendra Adams, CFO, sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 a share, worth $122K in total on Nov 12, 2026. Shares held after the trade: 337,150 (-11.8%).

Value
$122K
Shares
45,173
Price
$2.71
Role
CFO
Holding change
-11.8%
Trade date
Nov 12, 2026
4:10 PM ET Form 4
Insider Selling Life Time Group Holdings, Inc. LTH

Life Time Group Holdings Director John G. Danhakl Sells $78.9M of Stock

John G. Danhakl, Director, sold 1,683,651 shares of Life Time Group Holdings, Inc. at $46.86 a share, worth $78.9M in total on Nov 10, 2026. Shares held after the trade: 491,915 (-77.4%).

Value
$78.9M
Shares
1,683,651
Price
$46.86
Role
Director
Holding change
-77.4%
Trade date
Nov 10, 2026
4:10 PM ET 8-K
Leadership Change Independent Bank Corp INDB

Independent Bank Leadership Change

James O. Morton will retire from the Boards of Directors of Independent Bank Corp. and Rockland Trust Company effective November 15, 2026. His retirement is in accordance with the company's Governance Principles, which require directors to retire upon reaching the age of 72. Following his departure, the board size will be reduced from 14 to 13 members.

4:10 PM ET Form 4
Insider Selling Bandwidth Inc. BAND

Bandwidth Insider Douglas A. Suriano Sells $177K of Stock

Douglas A. Suriano sold 3,800 shares of Bandwidth Inc. at $46.21 to $47.11 a share (average $46.52) in 2 transactions, worth $177K in total on Nov 12, 2026. Shares held after the trade: 41,610 (-3.0%).

Value
$177K
Shares
3,800
Average price
$46.52
Holding change
-3.0%
Trade date
Nov 12, 2026
4:10 PM ET Form 4
Insider Selling Vaxcyte, Inc. PCVX

Vaxcyte Chief Technical Ops Officer Harpreet S. Dhaliwal Sells $1.15M of Stock

Harpreet S. Dhaliwal, Chief Technical Ops Officer, sold 17,000 shares of Vaxcyte, Inc. at $67.33 to $68.82 a share (average $67.83) in 3 transactions, worth $1.15M in total on Nov 11, 2026. Shares held after the trade: 68,085 (-0.8%).

Value
$1.15M
Shares
17,000
Average price
$67.83
Role
Chief Technical Ops Officer
Holding change
-0.8%
Trade date
Nov 11, 2026
4:10 PM ET 10-Q
Financial Results TaoWeave, Inc. TWAV

TaoWeave Q3 2026 Results: Turns Profitable, Net Income $1.54M

TaoWeave, Inc. reported its Q3 2026 results, highlighting significant activity in its Digital Assets segment, including unrealized gains from revaluations and realized gains from asset sales. The company also managed complex equity transactions involving Series F Preferred Stock and various warrant exercises, while maintaining distinct reporting for its Managed Services and Collaboration Products segments.

Key figure
Net income $1.54M
4:09 PM ET 10-Q
Financial Results TherapeuticsMD, Inc. TXMD

TherapeuticsMD Q3 2026 Results: Net Income $491K, Up 223.0% YoY

TherapeuticsMD reported net income of $0.49 million for the quarter ended September 30, 2026, compared to $0.15 million in the prior year period, driven by increased license revenue from its royalty-based business model. The company maintained a stable balance sheet with $10.4 million in cash and total stockholders' equity of $27.6 million.

Key figure
Net income $491K · +223.0% YoY
4:09 PM ET 8-K
Financial Results IEH Corp IEHC

IEH Financial Results

IEH Corporation reported record financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 51% year-over-year to $10.7 million. The company achieved a record backlog exceeding $56 million and returned to profitability with net income of $1.36 million compared to a net loss in the prior year period.

Term
Q2 2027

“As great as this year’s first quarter was, the second quarter exceeded it by every measure. The first quarter’s record revenue of $10 million was eclipsed by this quarter’s $10.7 million. Similarly, our operating profit increased 57%, and our net income and earnings per share both more than doubled.”

Dave Offerman, President and CEO of IEH Corporation

“We shattered our previous backlog record by 40%, and we continue to hire and add capacity and equipment to meet the surge in demand in the defense, commercial aerospace, space and medical markets we serve.”

Dave Offerman, President and CEO of IEH Corporation
4:09 PM ET 8-K
Business Update Incyte Corp INCY

Incyte Business Update

Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.

4:09 PM ET Form 4
Insider Selling Silvaco Group, Inc. SVCO

Silvaco Group Insider Candace Jackson Sells $22.4K of Stock

Candace Jackson sold 3,000 shares of Silvaco Group, Inc. at $7.45 a share, worth $22.4K in total on Nov 12, 2026. Shares held after the trade: 41,722 (-6.7%).

Value
$22.4K
Shares
3,000
Price
$7.45
Holding change
-6.7%
Trade date
Nov 12, 2026
4:09 PM ET 10-Q
Financial Results Seneca Bancorp, Inc. SNNF

Seneca Bancorp Q3 2026 Results: Net Income $86K, Down 53.5% YoY

Seneca Bancorp, Inc. reported a net income of $129,000 for the nine months ended September 30, 2026, compared to $137,000 in the prior year period. While net interest income increased significantly to $7.7 million, the results were impacted by higher noninterest expenses, including a $262,000 impairment of long-lived assets and increased compensation costs.

Key figure
Net income $86K · -53.5% YoY
4:09 PM ET 10-Q
Financial Results Boston Omaha Corp BOC

Boston Omaha Q3 2026 Results: Net Loss of $192K, Loss Narrows

Boston Omaha Corporation reported total revenues of $22.2 million for the third quarter of 2026, a slight increase from $21.9 million in the prior year. The company recorded a net loss attributable to common stockholders of $0.2 million for the quarter, an improvement from a $2.6 million loss in Q3 2025, primarily driven by equity in income of unconsolidated affiliates and income from discontinued operations.

Key figure
Net loss $192K
4:09 PM ET 10-Q
Financial Results Prospect Floating Rate & Alternative Income Fund, Inc. PFLOAT

Prospect Floating Rate & Alternative Income Fund Q1 2026 Results: Turns Profitable, Net Income $1.24M

Prospect Floating Rate & Alternative Income Fund, Inc. reported total investment income of $2.05 million for the quarter ended September 30, 2026, a slight decrease from $2.19 million in the prior year period. Net assets increased to $38.01 million from $37.10 million at fiscal year-end, while the net asset value per share for Class A and Class I shares decreased slightly to $3.88.

Key figure
Net income $1.24M
4:09 PM ET 10-Q
Financial Results Curis Inc CRIS

Curis Q3 2026 Results: Net Loss of $8.12M, Loss Widens

Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $8.12M
4:09 PM ET 10-Q
Financial Results Lisata Therapeutics, Inc. LSTA

Lisata Therapeutics Q3 2026 Results: Net Loss of $6.79M, Loss Widens

Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.

Key figure
Net loss $6.79M
4:09 PM ET 8-K
Loan & Debt Science Applications International Corp SAIC

Science Applications International $500M Debt Financing with Truist Bank

Science Applications International Corporation (SAIC) closed a private offering of $500 million in 6.750% Senior Notes due 2034. The company used the net proceeds of approximately $493 million to redeem its outstanding 4.875% Senior Notes due 2028 and for general corporate purposes.

Value
$500M
Counterparty
Truist Bank
Term
through 2034
4:09 PM ET 10-Q
Financial Results OptimizeRx Corp OPRX

OptimizeRx Q3 2026 Results: Net Income $1.2M, Up 53.4% YoY

For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.

Key figure
Net income $1.2M · +53.4% YoY
4:09 PM ET 8-K
Financial Results Vistagen Therapeutics, Inc. VTGN

Vistagen Therapeutics Financial Results

Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.

Term
Q2 2027

“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”

Shawn Singh, President and Chief Executive Officer of Vistagen

“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”

Shawn Singh, President and Chief Executive Officer of Vistagen
4:09 PM ET 10-Q
Financial Results Werewolf Therapeutics, Inc. HOWL

Werewolf Therapeutics Q3 2026 Results: Net Loss of $9.88M, Loss Narrows

Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.

Key figure
Net loss $9.88M
4:08 PM ET 8-K
Financial Results Inhibrx Biosciences, Inc. INBX

Inhibrx Biosciences Financial Results

Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.

Term
Q3 2026
4:08 PM ET 10-Q
Financial Results Republic Digital Acquisition Co RDAG

Republic Digital Acquisition Q3 2026 Results: Net Income $2.75M, Down 11.2% YoY

Republic Digital Acquisition Company is a special purpose acquisition company (SPAC) that reported 30,000,000 Class A and 7,500,000 Class B ordinary shares outstanding as of November 13, 2026. The company's cash position decreased from $1,016,713 at the end of 2025 to $643,377 as of September 30, 2026, as it continues to seek an initial business combination within its designated 24-month period.

Key figure
Net income $2.75M · -11.2% YoY
4:08 PM ET 10-Q
Financial Results Royalty Management Holding Corp RMCO

Royalty Management Holding Q3 2026 Results: Turns Profitable, Net Income $19.5K

For the nine months ended September 30, 2026, Royalty Management Holding Corp reported total revenue of $5.63 million, a significant increase from $3.55 million in the prior year, primarily driven by environmental services. Despite the revenue growth, the company realized a net loss of $257,687 for the period, though this was an improvement over the $317,131 net loss reported in the same period of 2025.

Key figure
Net income $19.5K
4:08 PM ET 10-Q
Financial Results Adaptin Bio, Inc. APTN

Adaptin Bio Q3 2026 Results: Net Loss of $957K, Loss Narrows

Adaptin Bio, Inc. reported a net loss of $3.31 million for the nine months ended September 30, 2026, compared to a $3.80 million loss in the prior year period. The company remains in the development stage with no revenue, maintaining a stockholders' deficit of $1.67 million and a cash balance of $430,333 as of the reporting date.

Key figure
Net loss $957K
4:08 PM ET 10-Q
Financial Results Digimarc Corp DMRC ▶ Call

Digimarc Q3 2026 Results: Net Loss of $8.09M, Loss Narrows

Digimarc reported a total revenue of $6.4 million for the third quarter of 2026, a decrease from $7.6 million in the prior year, primarily driven by lower subscription revenue. The company's net loss narrowed slightly to $7.9 million for the quarter, while cash and cash equivalents increased to $20.7 million as of September 30, 2026.

Key figure
Net loss $8.09M
4:08 PM ET 10-Q
Financial Results HWH International Inc. ESYN

EnerSyn Global Q3 2026 Results: Net Loss of $3M, Loss Widens

EnerSyn Global Inc. reported a significant increase in total assets to $17.8 million as of September 30, 2026, driven by a substantial cash infusion and common stock issuances. However, the company experienced a widened net loss of $3.4 million for the nine months ended September 30, 2026, primarily due to a sharp rise in general and administrative expenses.

Key figure
Net loss $3M
4:08 PM ET 10-Q
Financial Results Rocket One Inc. RKTO

Rocket One Q3 2026 Results: Net Loss of $2.68M, Loss Narrows

Rocket One Inc. reported a total asset increase to $8.66 million as of September 30, 2026, driven by new intangible assets and goodwill, despite a decrease in cash and cash equivalents. The company's accumulated deficit grew to $82.09 million, reflecting ongoing operational losses during its strategic repositioning into orbital and defense technologies.

Key figure
Net loss $2.68M
4:08 PM ET Form 4
Insider Selling Ibotta, Inc. IBTA

Ibotta 10% Owner KDT Ibotta Holdings LLC Sells $16.4M of Stock

KDT Ibotta Holdings LLC, 10% Owner, sold 274,999 shares of Ibotta, Inc. at $58.97 to $59.97 a share (average $59.55) in 4 transactions, worth $16.4M in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 3,014,129 (-3.2%).

Value
$16.4M
Shares
274,999
Average price
$59.55
Role
10% Owner
Holding change
-3.2%
Trade date
Nov 11, 2026 to Nov 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.